The Senate Judiciary Committee today voted 16 to 5 to report the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act) to the Senate floor.
The Senate Judiciary Committee today voted 16 to 5 to report the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act) to the Senate floor.
Under the CREATES Act, a generic or biosimilar developer can bring a civil action against an innovator drug company if it refuses to make available enough samples of a product for testing. It also allows the FDA to approve alternative Risk Evaluation and Mitigation Strategy (REMS) programs if a generic or biosimilar developer and the innovator company are unable to arrive at a single shared system.
The legislation, sponsored by Senator Patrick Leahy, D-Vermont, was first introduced in a different version in 2016 and, since then, has enjoyed broad bipartisan support. However, the bill languished without a vote as it faced opposition from pharmaceutical companies; The Hill reported in April 2018 that the Pharmaceutical Research and Manufacturers of America spent approximately $10 million on lobbying efforts—including efforts to halt progress of the CREATES Act—in the first quarter of this year.
Among the most vocal supporters of the bill is former Representative Henry Waxman, D-California, who co-sponsored (with Senator Orrin Hatch, R-Utah) the legal foundation for the US generics drug market: The Drug Price Competition and Patent Term Restoration Act of 1984, referred to colloquially as “Hatch-Waxman.”
Despite Waxman’s support, however, 1 of the 5 senators to vote against reporting the CREATES Act to the floor was Hatch; before the vote, Hatch noted that he has a “…keen interest in ensuring that we have a well-functioning generics industry,” and added that, while the CREATES Act has a “laudable goal,” its monetary caps on damages that generic and biosimilar development companies can seek are, in his view, high enough to incentivize “nonmeritorious litigation.”
Hatch added that he will be sponsoring an amendment to the bill designed to limit the challenges that generic and biosimilar developers can bring against innovator product sponsors. His amendment would force a challenger to choose between bringing a Hatch-Waxman suit or seeking an inter partes review proceeding; a company could not pursue both avenues to challenge a drug patent. The provisions of the amendment would also apply to post-grant review proceedings and to biosimilar litigation, he said.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.